Skip to main content

Table 7 Logistic regression analysis

From: Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study

Variables OR (95% CI) p-value
Gender
 Female 1 (0.7–1.6) 0.7
Age categories
  ≤ 30 Reference
 31–40 0.8 (0.4–1.7) 0.6
 41–50 1.4 (0.8–2.6) 0.3
  > 50 1 (0.6–1.7) 1
Overall prescribed drugs
  ≤ 5 Reference
 6–7 3.5 (0.9–12.9) 0.07
 8–9 8.9 (2.6–30.3) <0.001
  ≥ 10 25.2 (7.7–82.2) <0.001
QT drugs
 1 Reference
 2 25.4 (11.2–57.5) <0.001
  ≥ 3 21 (9.2–48) <0.001
Diagnoses
 Acute lymphoblastic leukemia Reference
 Breast cancer 3.7 (1.2–11.6) 0.03
 Chronic lymphocytic leukemia 3.5 (0.8–15.9) 0.1
 Gastrointestinal cancer 4 (1.3–13) 0.02
 Genitourinary cancer 2.7 (0.7–10.9) 0.2
 Gynecologic cancer 3.1 (0.9–11.2) 0.08
 Musculoskeletal cancer 2.5 (0.5–12) 0.3
 Non hodgkin lymphoma 0.3 (0.07–1.3) 0.1
 Others 1 (0.3–3.3) 0.9
Anticancer drugs
  ≤ 2 Reference  
  > 2 0.6 (0.4–0.9) 0.02
Supportive care drugs
  ≤ 3 Reference  
 4–5 4.3 (1.9–9.5) <0.001
 6–8 8.1 (3.7–17.7) <0.001
  > 8 12.2 (4.9–30.5) <0.001